

DAFTAR PUSTAKA

1. Wahyuni A, Nisa K. Pengaruh Aktivitas dan Latihan Fisik terhadap Fungsi Kognitif pada Penderita Demensia. *Majority*. 2016;5(4):12-16.
2. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. *J Cereb Blood Flow Metab*. 2016;36(1):172-186.
3. Kakutani S, Watanabe H, Murayama N. Green tea intake and risks for dementia, Alzheimer's disease, mild cognitive impairment, and cognitive impairment: A systematic review. *Nutrients*. 2019;11(5).
4. Serrano-Pozo A, Growdon JH. Is Alzheimer's Disease Risk Modifiable? *J Alzheimer's Dis*. 2019;67(3):795-819.
5. Bare Y. Analisis senyawa fitosterol Cymbopogon citratus dan Curcuma longa. 2021;7.
6. Siska EM. Darmabakti Cendekia: Caregiver Training on Care for People With. 2020;2:1-3.
7. Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M. Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS. *J Prev Alzheimer's Dis*. 2020;7(1):29-36.
8. Ary K, Pattni M, Udayana U. Beta-Amyloid As Pathogenesis of Alzheimer Disease. *e-Jurnal Med Udayana*. 2013;2(8):1306-1317.
9. Nisa KM, Lisiswanti R. Faktor Risiko Demensia Alzheimer. *Majority*. 2016;5(4):86.
<http://juke.kedokteran.unila.ac.id/index.php/majority/article/view/890>
10. Pattni K. Beta-Amyloid sebagai Patogenesis pada Penyakit Alzheimer. Published online 2014:12.
11. Wilson H, Pagano G, Politis M. Dementia spectrum disorders: lessons learnt from decades with PET research. *J Neural Transm*. 2019;126(3):233-251.
12. Tiwari S, Venkata A, Kaushik A, Adriana Y NM. Alzheimer's Disease Diagnostics And Therapeutics Market. [Enfermedad de Alzheimer: patogenia, diagnóstico y terapéutica]. *Int J Nanomedicine*. 2019;Jul 2019(14):5541-5554.
13. Ada N, Wilson WT, Zhang MW, Ho CS, Husain SF. IL-1 β , IL-6, TNF- α and CRP in Elderly Patients with Depression or Alzheimer's disease: Systematic Review and Meta-Analysis. 2018;(August 2017):1-12.
14. Duncan T, Valenzuela M. Alzheimer's disease, dementia, and stem cell therapy. *Stem Cell Res Ther*. 2017;8(1):1-9.
15. Mustafa HN. Neuro-amelioration of cinnamaldehyde in aluminum-induced Alzheimer's disease rat model. *J Histotechnol*. 2020;43(1):11-20.
16. Sun C, Wang L, Wang H, et al. Single-cell RNA-seq highlights heterogeneity in human primary Wharton's jelly mesenchymal stem / stromal cells cultured in vitro. Published online 2020:1-16.
17. Lee J, Kwon SJ, Kim JH, et al. Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. *Sci Rep*. 2019;(January 2018):1-9.

18. Lee M, Ban JJ, Yang S, Im W, Kim M. The exosome of adipose-derived stem cells reduces β -amyloid pathology and apoptosis of neuronal cells derived from the transgenic mouse model of Alzheimer's disease. *Brain Res.* 2018;1691:87-93.
19. Bodart-santos V, Carvalho LRP De, Godoy MA De, et al. Extracellular vesicles derived from human Wharton ' s jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid- β oligomers. 2019;5:1-13.
20. Koepsell H. Glucose transporters in brain in health and disease. *Pflugers Arch Eur J Physiol.* 2020;472(9):1299-1343.
21. Marko DM, Foran G, Vlaveciski F, et al. Interleukin-6 Treatment Results in GLUT4 Translocation and AMPK Phosphorylation in Neuronal SH-SY5Y Cells. *Cells.* 2020;9(5).
22. McNay EC, Pearson-Leary J. GluT4: A central player in hippocampal memory and brain insulin resistance. *Exp Neurol.* 2020;323:113076.
23. Pearson-Leary J, McNay EC. Novel roles for the insulin-regulated glucose transporter-4 in hippocampally dependent memory. *J Neurosci.* 2016;36(47):11851-11864.
24. Das TK, Chakrabarti SK, Zulkipli IN, Abdul Hamid MRW. Curcumin Ameliorates the Impaired Insulin Signaling Involved in the Pathogenesis of Alzheimer's Disease in Rats. *J Alzheimer's Dis Reports.* 2019;3(1):59-70.
25. Mullins RJ, Diehl TC, Chia CW, Kapogiannis D. Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer ' s Disease. 2017;9(May):1-16.
26. Isaacson RS, Ganzer CA, Hristov H, et al. The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach. *Alzheimer's Dement.* 2018;14(12):1663-1673.
27. Xuefeng Chen, et al 2011. Female Sex and Alzheimer's Risk: The Menopause Connection. *Physiol Behav.* 2011;176(10):139-148.
28. Robinson M, Lee BY, Hane FT. Recent Progress in Alzheimer's Disease Research, Part 2: Genetics and Epidemiology. *J Alzheimers Dis.* 2017;57(2):317-330.
29. Aisen PS, Cummings J, Jack CR, et al. On the path to 2025: Understanding the Alzheimer's disease continuum. *Alzheimer's Res Ther.* 2017;9(1):1-10.
30. Crous-Bou M, Minguillón C, Gramunt N, Molinuevo JL. Alzheimer's disease prevention: From risk factors to early intervention. *Alzheimer's Res Ther.* 2017;9(1):1-9.
31. Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and alzheimer's disease: Role of insulin signalling and therapeutic implications. *Int J Mol Sci.* 2018;19(11).
32. Budiman HM, Berawi KN, Bustomi EC, et al. Mekanisme Rokok dalam Meningkatkan Risiko Penyakit Alzheimer Smoking Mechanism in Increasing Risk of Alzheimer ' s Disease. *J Kedokt.* 2018;7(3):234-240.
33. Thakur AK, Kamboj P, Gosmawi K, Ahuja K. Pathophysiology and management of alzheimer's disease. 2018;(an overview. *J Anal Pharm Res.*):7(2):226–235.
34. Cummings J, Feldman HH, Scheltens P. The "rights" of precision drug development for Alzheimer's disease. *Alzheimer's Res Ther.* 2019;11(1):1-

- 14.
35. Jin H, Guan S, Wang R, et al. The Distribution of Urinary Alzheimer-Associated Neuronal Thread Protein and Its Association with Common Chronic Diseases in the General Population. *J Alzheimers Dis.* 2018;65(2):433-442.
 36. Reza-Zaldivar EE, Hernández-Sapiéns MA, Minjarez B, Gutiérrez-Mercado YK, Márquez-Aguirre AL, Canales-Aguirre AA. Potential Effects of MSC-Derived Exosomes in Neuroplasticity in Alzheimer's Disease. *Front Cell Neurosci.* 2018;12(September):1-16.
 37. Vasic V, Barth K, Schmidt MHH. Neurodegeneration and neuro-regeneration— Alzheimer's disease and stem cell therapy. *Int J Mol Sci.* 2019;20(17).
 38. Stefanska K. Human Wharton's Jelly—Cellular Specificity, Stemness Potency, Animal Models, and Current Application in Human Clinical Trials. Published online 2020:9.
 39. Dabrowska S, Sypecka J, Jablonska A, et al. Neuroprotective Potential and Paracrine Activity of Stromal Vs . Culture-Expanded hMSC Derived from Wharton Jelly under Co-Cultured with Hippocampal Organotypic Slices. Published online 2017.
 40. Kangari P, Talaei-Khozani T, Razeghian-Jahromi I, Razmkhah M. Mesenchymal stem cells: amazing remedies for bone and cartilage defects. *Stem Cell Res Ther.* 2020;11(1):1-21.
 41. Putra MR. Hubungan Antara Tingkat Keparahan Neuropati Diabetik Dengan Gangguan Fungsi Kognitif Pada Penderita Diabetes Melitus. Published online 2019:1-95.
 42. Kim H, Na DL, Lee NK, Kim AR. Intrathecal Injection in A Rat Model : A Potential Route to Deliver Human Wharton ' s Jelly-Derived Mesenchymal Stem Cells into the Brain. :1-12.
 43. Aboelwafa HR, El-Kott AF, Abd-Ella EM, Yousef HN. The possible neuroprotective effect of silymarin against aluminum chloride-prompted alzheimer's-like disease in rats. *Brain Sci.* 2020;10(9):1-21.
 44. Dwi Yarni S. Pengaruh Pemberian Mesenchymal Stem Cell Wharton Jelly Terhadap Ekspresi Gen *Calm1* Dan *Casp9* Pada Tikus Alzheimer.; 2021.
 45. Indriati M. Deteksi kandungan babi pada produk olahan daging menggunakan metode multipleks pcr di kabupaten pandeglang. *J Biol dan Pembelajarannya.* 2021;16(1):1-10.
 46. Wang L. Entry and Deposit of Aluminum in the Brain. :39-51.
 47. Yu H, Yuan B, Chu Q, Wang C, Bi H. Protective roles of isoastilbin against Alzheimer's disease via Nrf2-mediated antioxidation and anti-apoptosis. *Int J Mol Med.* 2019;43(3):1406-1416.
 48. Blázquez E, Velázquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: Its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and alzheimer's disease. *Front Endocrinol (Lausanne).* 2014;5(OCT):1-21.
 49. De La Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in alzheimers disease. *Drugs.* 2012;72(1):49-66.
 50. Saleh RA, Eissa TF, Abdallah DM, Saad MA. Peganum harmala enhanced

- GLP - 1 and restored insulin signaling to alleviate - Alzheimer - like pathology model. *Sci Rep*. Published online 2021:1-14.
51. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the Risk of Dementia , Alzheimer ' s Disease and Vascular Cognitive Aging. *Dement Geriatr Cogn Disord*. 2002;1:77–83.
 52. Costa LA, Eiro N, Fraile M, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. *Cell Mol Life Sci*. 2021;78(2):447-467.
 53. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases. *Cells*. 2019;8(12).
 54. Wang AYL, Loh CY, Shen HH, et al. Human wharton's jelly mesenchymal stem cell-mediated sciatic nerve recovery is associated with the upregulation of regulatory t cells. *Int J Mol Sci*. 2020;21(17):1-14.
 55. Liang J, Wu S, Zhao H, et al. Neuroscience Letters Human umbilical cord mesenchymal stem cells derived from Wharton ' s jelly differentiate into cholinergic-like neurons in vitro. *Neurosci Lett*. 2013;532:59-63.
 56. Yang H, Xie ZH, Wei LF, et al. Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an A β PP/PS1 transgenic mouse model. *Stem Cell Res Ther*. 2013;4(4).
 57. Gao LR, Zhang NK, L. W, Y. Z, H.H. T. Overexpression of apelin in Wharton' jelly mesenchymal stem cell reverses insulin resistance and promotes pancreatic β cell proliferation in type 2 diabetic rats 11 Medical and Health Sciences 1103 Clinical Sciences. *Stem Cell Res Ther*. (1):1-14.

